{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:44:32Z","timestamp":1782744272734,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007210","name":"RWTH Aachen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007210","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Ocrelizumab (OCR) is an effective anti-CD20 therapy for relapsing-remitting and primary progressive multiple sclerosis (MS), but long-term effects on humoral immunity in real-world settings remain incompletely characterized. We investigated longitudinal changes in serum immunoglobulins, explored factors associated with hypogammaglobulinemia, and assessed associations with infection risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective, single-center observational study, adult patients with MS treated with OCR between 2018 and 2023 were included after \u2265\u20092 treatment cycles. Patients underwent standardized clinical, radiological, and laboratory follow-up, including serial measurements of serum immunoglobulins and varicella-zoster virus (VZV) serology. Infections were graded according to CTCAE criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 116 patients (81% relapsing-remitting MS; median follow-up 2.3 years), approximately one-third developed lower limit of normal (LLN) IgM and one-sixth LLN IgG. Declines in immunoglobulins were class-specific and treatment-duration-dependent, most pronounced for IgM. Low baseline immunoglobulin levels were the strongest factors associated with LLN values, whereas demographic and disease-related factors were not. Prior immunotherapy, particularly fingolimod or interferon, was associated with hypogammaglobulinemia. Severe infections were rare (1.1 per 100 patient-years) and not consistently associated with LLN immunoglobulins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>OCR induced predictable, class-specific declines in immunoglobulins. Despite frequent hypogammaglobulinemia - particularly affecting IgM - no association with an increased short- to mid-term risk of clinically relevant infections was observed, although limited event numbers restrict conclusions. These findings support individualized immunoglobulin monitoring focused on patients with low baseline levels or prior immunotherapy exposure and underscore the need for prospective studies to define clinically meaningful thresholds for intervention during long-term anti-CD20 therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-026-00509-0","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:51:10Z","timestamp":1782741070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal changes of serum immunoglobulins under ocrelizumab: factors associated with hypogammaglobulinemia and infection risk in a real-world multiple sclerosis cohort"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1879-5589","authenticated-orcid":false,"given":"Amelie","family":"Bohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona S.","family":"Teubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone C.","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Waschbisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"3","key":"509_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H. P., Hemmer, B., et al. (2017). Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal Of Medicine, 376(3), 221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"New England Journal Of Medicine"},{"issue":"3","key":"509_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., et al. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal Of Medicine, 376(3), 209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"New England Journal Of Medicine"},{"issue":"1","key":"509_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00415-022-11350-1","volume":"270","author":"N Capasso","year":"2023","unstructured":"Capasso, N., Palladino, R., Cerbone, V., Spiezia, A. L., Covelli, B., Fiore, A., et al. (2023). Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study. Journal Of Neurology, 270(1), 272\u2013282. https:\/\/doi.org\/10.1007\/s00415-022-11350-1","journal-title":"Journal Of Neurology"},{"issue":"16","key":"509_CR4","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/wnl.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser, S. L., Kappos, L., Montalban, X., Craveiro, L., Chognot, C., Hughes, R., et al. (2021). Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology, 97(16), e1546\u2013e59. https:\/\/doi.org\/10.1212\/wnl.0000000000012700","journal-title":"Neurology"},{"issue":"6","key":"509_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","volume":"4","author":"A Schuckmann","year":"2023","unstructured":"Schuckmann, A., Steffen, F., Zipp, F., Bittner, S., & Pape, K. (2023). Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis. Med, 4(6), 361\u201372e3. https:\/\/doi.org\/10.1016\/j.medj.2023.05.001","journal-title":"Med"},{"key":"509_CR6","doi-asserted-by":"publisher","first-page":"105009","DOI":"10.1016\/j.msard.2023.105009","volume":"79","author":"E Alvarez","year":"2023","unstructured":"Alvarez, E., Longbrake, E. E., Rammohan, K. W., Stankiewicz, J., & Hersh, C. M. (2023). Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord, 79, 105009. https:\/\/doi.org\/10.1016\/j.msard.2023.105009","journal-title":"Mult Scler Relat Disord"},{"key":"509_CR7","doi-asserted-by":"publisher","unstructured":"Nobile, S., & Beauchemin, P. (2024). Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort. Canadian Journal Of Neurological Sciences, 1\u20138. https:\/\/doi.org\/10.1017\/cjn.2024.21","DOI":"10.1017\/cjn.2024.21"},{"issue":"6","key":"509_CR8","doi-asserted-by":"publisher","first-page":"e00760","DOI":"10.1016\/j.neurot.2025.e00760","volume":"22","author":"M Perriguey","year":"2025","unstructured":"Perriguey, M., Rigollet, C., Freeman, S. A., Graille-Avy, L., Lafontaine, J. C., Lemarchant, B., et al. (2025). Prevalence of hypogammaglobulinemia after non-anti-CD20 therapies and impact of switching to rituximab\/ocrelizumab in multiple sclerosis. Neurotherapeutics, 22(6), e00760. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00760","journal-title":"Neurotherapeutics"},{"key":"509_CR9","doi-asserted-by":"publisher","first-page":"103798","DOI":"10.1016\/j.msard.2022.103798","volume":"62","author":"M Habek","year":"2022","unstructured":"Habek, M., Piska\u010d, D., Gabeli\u0107, T., Barun, B., Adamec, I., & Krbot Skori\u0107, M. (2022). Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab. Mult Scler Relat Disord, 62, 103798. https:\/\/doi.org\/10.1016\/j.msard.2022.103798","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"509_CR10","doi-asserted-by":"publisher","first-page":"e000108","DOI":"10.1136\/bmjno-2020-000108","volume":"3","author":"K Smoot","year":"2021","unstructured":"Smoot, K., Chen, C., Stuchiner, T., Lucas, L., Grote, L., & Cohan, S. (2021). Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study. BMJ Neurology Open, 3(2), e000108.","journal-title":"BMJ Neurology Open"},{"issue":"6","key":"509_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00415-025-13133-w","volume":"272","author":"L Davies","year":"2025","unstructured":"Davies, L., Shehadeh, R., Watkins, W. J., Jolles, S., Robertson, N. P., & Tallantyre, E. C. (2025). Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. Journal Of Neurology, 272(6), 415. https:\/\/doi.org\/10.1007\/s00415-025-13133-w","journal-title":"Journal Of Neurology"},{"issue":"9","key":"509_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","volume":"19","author":"HS Ng","year":"2020","unstructured":"Ng, H. S., Rosenbult, C. L., & Tremlett, H. (2020). Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opinion on Drug Safety, 19(9), 1069\u20131094. https:\/\/doi.org\/10.1080\/14740338.2020.1807002","journal-title":"Expert Opinion on Drug Safety"},{"key":"509_CR13","doi-asserted-by":"publisher","first-page":"105830","DOI":"10.1016\/j.msard.2024.105830","volume":"90","author":"B Silva","year":"2024","unstructured":"Silva, B., Casales, F., Donoso, C. B., Varela, L., Heriz, A., Gonzalez, C., et al. (2024). Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study. Mult Scler Relat Disord, 90, 105830. https:\/\/doi.org\/10.1016\/j.msard.2024.105830","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"509_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., et al. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, 17(2), 162\u2013173. https:\/\/doi.org\/10.1016\/s1474-4422(17)30470-2","journal-title":"Lancet Neurology"},{"key":"509_CR15","unstructured":"U.S. Department of Health and Human Services NIoH, National Cancer Institute (2024). Common Terminology Criteria for Adverse Events (CTCAE) v5.0 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf Accessed November 22."},{"issue":"4","key":"509_CR16","doi-asserted-by":"publisher","first-page":"205521732096450","DOI":"10.1177\/2055217320964505","volume":"6","author":"B Evertsson","year":"2020","unstructured":"Evertsson, B., Hoyt, T., Christensen, A., Nimer, F. A., Foley, J., & Piehl, F. (2020). A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal\u2013Experimental Translational and Clinical, 6(4), 2055217320964505.","journal-title":"Multiple Sclerosis Journal\u2013Experimental Translational and Clinical"},{"key":"509_CR17","doi-asserted-by":"publisher","first-page":"109894","DOI":"10.1016\/j.clim.2024.109894","volume":"259","author":"L Beckers","year":"2024","unstructured":"Beckers, L., Baeten, P., Popescu, V., Swinnen, D., Cardilli, A., Hamad, I., et al. (2024). Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab. Clin Immunol, 259, 109894. https:\/\/doi.org\/10.1016\/j.clim.2024.109894","journal-title":"Clin Immunol"},{"key":"509_CR18","doi-asserted-by":"publisher","first-page":"578066","DOI":"10.1016\/j.jneuroim.2023.578066","volume":"377","author":"V Mears","year":"2023","unstructured":"Mears, V., Jakubecz, C., Seeco, C., Woodson, S., Serra, A., & Abboud, H. (2023). Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD. Journal Of Neuroimmunology, 377, 578066. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578066","journal-title":"Journal Of Neuroimmunology"},{"key":"509_CR19","doi-asserted-by":"publisher","first-page":"175628641987834","DOI":"10.1177\/1756286419878340","volume":"12","author":"G Zoehner","year":"2019","unstructured":"Zoehner, G., Miclea, A., Salmen, A., Kamber, N., Diem, L., Friedli, C., et al. (2019). Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Therapeutic Advances In Neurological Disorders, 12, 1756286419878340. https:\/\/doi.org\/10.1177\/1756286419878340","journal-title":"Therapeutic Advances In Neurological Disorders"},{"issue":"Pt 6","key":"509_CR20","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/brain\/awn077","volume":"131","author":"M Krumbholz","year":"2008","unstructured":"Krumbholz, M., Faber, H., Steinmeyer, F., Hoffmann, L. A., K\u00fcmpfel, T., Pellkofer, H., et al. (2008). Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain, 131(Pt 6), 1455\u20131463. https:\/\/doi.org\/10.1093\/brain\/awn077","journal-title":"Brain"},{"key":"509_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jneuroim.2018.11.001","volume":"326","author":"A Monteiro","year":"2019","unstructured":"Monteiro, A., Cruto, C., Rosado, P., Rosado, L., Fonseca, A. M., & Paiva, A. (2019). Interferon-beta treated-multiple sclerosis patients exhibit a decreased ratio between immature\/transitional B cell subset and plasmablasts. Journal Of Neuroimmunology, 326, 49\u201354. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.11.001","journal-title":"Journal Of Neuroimmunology"},{"issue":"7","key":"509_CR22","doi-asserted-by":"publisher","first-page":"e0235449","DOI":"10.1371\/journal.pone.0235449","volume":"15","author":"CL Kemmerer","year":"2020","unstructured":"Kemmerer, C. L., Pernpeintner, V., Ruschil, C., Abdelhak, A., Scholl, M., Ziemann, U., et al. (2020). Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-\u03b2, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab. PLoS One, 15(7), e0235449. https:\/\/doi.org\/10.1371\/journal.pone.0235449","journal-title":"PLoS One"},{"issue":"6972","key":"509_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"M Matloubian","year":"2004","unstructured":"Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., et al. (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 427(6972), 355\u2013360. https:\/\/doi.org\/10.1038\/nature02284","journal-title":"Nature"},{"key":"509_CR24","doi-asserted-by":"publisher","first-page":"175628642311626","DOI":"10.1177\/17562864231162661","volume":"16","author":"A Klein","year":"2023","unstructured":"Klein, A., Flaskamp, M., Berthele, A., Held, F., Muratovic, H., & Hemmer, B. (2023). The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study. Therapeutic Advances In Neurological Disorders, 16, 17562864231162661. https:\/\/doi.org\/10.1177\/17562864231162661","journal-title":"Therapeutic Advances In Neurological Disorders"},{"key":"509_CR25","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/j.clinph.2019.12.042","volume":"131","author":"T Derfuss","year":"2020","unstructured":"Derfuss, T., Weber, M., Hughes, R., Eggebrecht, J., Wang, Q., Sauter, A., et al. (2020). P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology, 131, e196. https:\/\/doi.org\/10.1016\/j.clinph.2019.12.042","journal-title":"Clinical Neurophysiology"},{"key":"509_CR26","doi-asserted-by":"publisher","first-page":"102988","DOI":"10.1016\/j.msard.2021.102988","volume":"52","author":"NR Oksbjerg","year":"2021","unstructured":"Oksbjerg, N. R., Nielsen, S. D., Blinkenberg, M., Magyari, M., & Sellebjerg, F. (2021). Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord, 52, 102988. https:\/\/doi.org\/10.1016\/j.msard.2021.102988","journal-title":"Mult Scler Relat Disord"},{"key":"509_CR27","doi-asserted-by":"publisher","first-page":"108554","DOI":"10.1016\/j.clim.2020.108554","volume":"223","author":"L Rapisarda","year":"2021","unstructured":"Rapisarda, L., Valentino, P., Barone, S., Torti, C., La Gamba, V., Fortunato, F., et al. (2021). Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab. Clin Immunol, 223, 108554. https:\/\/doi.org\/10.1016\/j.clim.2020.108554","journal-title":"Clin Immunol"},{"issue":"1","key":"509_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s42466-025-00377-0","volume":"7","author":"J Chen","year":"2025","unstructured":"Chen, J., Burmeister, T., Frankenstein, L., Laumeier, I., & Siffrin, V. (2025). Recurrent late-onset neutropenia after ofatumumab treatment in a case of multiple sclerosis. Neurol Res Pract, 7(1), 20. https:\/\/doi.org\/10.1186\/s42466-025-00377-0","journal-title":"Neurol Res Pract"},{"key":"509_CR29","doi-asserted-by":"publisher","first-page":"1380654","DOI":"10.3389\/fneur.2024.1380654","volume":"15","author":"A Elgenidy","year":"2024","unstructured":"Elgenidy, A., Abdelhalim, N. N., Al-Kurdi, M. A., Mohamed, L. A., Ghoneim, M. M., Fathy, A. W., et al. (2024). Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients. Frontiers In Neurology, 15, 1380654. https:\/\/doi.org\/10.3389\/fneur.2024.1380654","journal-title":"Frontiers In Neurology"},{"issue":"1","key":"509_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s42466-025-00379-y","volume":"7","author":"A Mrochen","year":"2025","unstructured":"Mrochen, A., Meuth, S. G., & Pfeuffer, S. (2025). Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis. Neurol Res Pract, 7(1), 25. https:\/\/doi.org\/10.1186\/s42466-025-00379-y","journal-title":"Neurol Res Pract"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00509-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-026-00509-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00509-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:51:20Z","timestamp":1782741080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42466-026-00509-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["509"],"URL":"https:\/\/doi.org\/10.1186\/s42466-026-00509-0","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the institutional ethics committee of the University Hospital RWTH Aachen (approval number: 23-181, date: 10.07.2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the retrospective nature of the study and the use of anonymized data, the requirement for informed consent was waived by the ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A. Bohn received travel and speaker honoraria from Novartis, Merck and Roche; F.S. Teubner reports no disclosures relevant to the manuscript; A. Waschbisch received travel and speaker honoraria from CSL Behring, Merck, and Roche; S.C. Tauber served on the scientific advisory board for Roche and Merck and received travel and speaker honoraria from Novartis, Teva, Merck, Roche and Biogen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}